Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

PHASE3CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 4, 2016

Study Completion Date

September 4, 2016

Conditions
Influenza
Interventions
DRUG

Nitazoxanide

Nitazoxanide 600 mg administered orally twice daily for five days

DRUG

Placebo

Placebo administered orally twice daily for five days

Trial Locations (28)

2088

Influence Study Site, Mosman

2100

Influence Study Site, Brookvale

2154

Influence Study Site, Castle Hill

3029

Influence Study Site, Tarneit

3806

Influence Study Site, Berwick

3939

Influence Study Site, Rosebud

3957

Influence Study Site, Lynbrook

4118

Influence Study Site, Browns Plains

4300

Influence Study Site, Springfield

19446

Influence Study Site, Lansdale

31401

Influence Study Site, Savannah

31904

Influence Study Site, Columbus

33319

Influence Study Site, Lauderdale Lakes

34744

Influence Study Site, Kissimmee

34769

Influence Study Site, Saint Cloud

38305

Influence Study Site, Jackson

57702

Influence Study Site, Rapid City

71913

Influence Study Site, Hot Springs

75024

Influence Study Site, Plano

76710

Influence Study Site, Waco

77058

Influence Study Site, Houston

78577

Influence Study Site, Pharr

78735

Influence Study Site, Austin

90717

Influence Study Site, Lomita

92805

Influence Study Site, Anaheim

93702

Influence Study Site, Fresno

00912

Influence Study Site, San Juan

00927

Influence Study Site, San Juan

All Listed Sponsors
lead

Romark Laboratories L.C.

INDUSTRY

NCT02612922 - Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza | Biotech Hunter | Biotech Hunter